Cerebras Systems

G42 supplied 87% of Cerebras’ $136.4 million in first-half-2024 revenue. G42 also committed $335 million to buy shares. The supplied reports do not show that the purchase closed.

The revenue share implies $118.7 million from G42, derived from Cerebras’ first-half sales; other customers supplied the remaining 13%. Cerebras reported a $66.6 million net loss for the same half. The proposed purchase would have given G42 a stake above 5%. Reuters reported a CFIUS review of the commitment in March 2025. Cerebras told Bloomberg later that month that it had resolved “all open issues.” Those reports address regulatory status, not a transfer of shares.

Cerebras Systems (CBRS, Nasdaq) builds wafer-scale chips for training and running AI models: one large piece of silicon per chip, rather than smaller dies cut from a wafer and wired together. Cerebras priced its IPO at $185 a share on May 13, 2026, above its raised $150–$160 range. Selling 30 million shares raised $5.55 billion, derived from that price and share count. By proceeds, it was the largest US tech listing of 2026 and the largest since Uber’s in 2019. Shares opened at $350 and closed their first day at $311.07, up 68% from the IPO price.

TEXXR first tagged Cerebras on September 1, 2017. A Forbes profile put its valuation at $860 million before it had shipped a product. Benchmark had led a $27 million Series A in 2016. A $250 million Series F in November 2021 put Cerebras at $4 billion, versus the 2017 valuation, and brought its cumulative funding to $720 million.

Sources floated an IPO in January 2024. TEXXR still marks that “considering an IPO” graph edge as rumored: by August 2026, it had sat unresolved for more than 900 days, although Cerebras listed in May. Cerebras filed confidentially in June 2024 and publicly that September. It withdrew that public filing in October 2025 after a $1.1 billion private raise valued it at $8.1 billion, versus $4 billion at the 2021 raise. A $1 billion Series H led by Tiger Global and joined by AMD valued Cerebras at $23 billion in February 2026, versus $8.1 billion after the prior raise. Cerebras filed publicly again in April. That second public filing led to the May listing; it was not withdrawn.

CNBC’s April 2026 account of the second IPO filing reported FY2025 revenue of $510 million, up 76% from about $289.8 million in FY2024, derived from CNBC’s stated growth rate. CNBC also reported FY2025 net income of $87.9 million, against an FY2024 net loss of $485 million. Those are the filing figures as reported by CNBC. This page does not use the conflicting FY2025 net-income figure in the DeadRisk market layer because the supplied records do not establish its accounting basis.

The DeadRisk market layer separately records FY2025 EBITDA of negative $110.8 million, versus negative $90.1 million in FY2024. Operating cash flow was negative $10.1 million versus positive $452.0 million; capex was $382.7 million versus $23.4 million; and free cash flow was negative $392.8 million versus positive $428.5 million. Year-end cash was $701.7 million versus $220.2 million, while debt was $261.8 million versus $40.7 million. These are market-layer figures, not a reconciliation to CNBC’s filing-reported net income.

TEXXR counts articles tagged Cerebras in its corpus by calendar quarter. It found one to four per quarter from 2023 through most of 2025, then 18 in Q1 2026 and 23 in Q2. Q2’s count was 5.75 times the earlier high of four, derived. Completed Q3 brought eight, down from Q2’s 23 and near the eight-quarter average of 7.7. These are coverage counts, not deployment counts.

TEXXR also extracts subject-predicate-object claims from those articles. Financial predicates supplied 57% of its Q2 2026 claims, versus 43% for all other predicates. The counterparties named that quarter did not overlap those in Q1 2024. IPO-quarter coverage increasingly cast Cerebras as Nvidia’s rival. The graph measures that framing, not competitive share.

G42 is the only customer the supplied reports also tie to a prospective equity purchase. The other named relationships do not establish a second customer-equity pairing or disclose how much those companies spend.

AWS said in March 2026 it would deploy Cerebras’ Wafer-Scale Engine for inference alongside its Trainium chips. TEXXR extracted 17 near-identical claims from same-day coverage of that one announcement, not 17 deployments. Mayo Clinic announced a healthcare-model partnership in January 2024, and Mistral partnered with Cerebras in February 2025.

TEXXR’s supplied source cards do not establish that OpenAI both committed to buy Cerebras compute and took, or agreed to take, equity. AMD invested in Cerebras, but the supplied records do not identify AMD as a customer. In the broader AI capex story, announcements cannot stand in for a disclosed revenue mix or measured utilization. That is where the street’s relationship count runs ahead of the data.

Positioning: how much of CBRS is sold short, on the record brokers file twice a month. It lags by design — read it as where the crowd stood, not where it stands.

• Customer mix and ownership. Look for Cerebras’ next largest-customer disclosure and a filing that distinguishes a committed stock purchase from shares bought or beneficially owned. Customer announcements alone cannot show diversification.
• Margins. Cerebras’ first public earnings report gave Q1 2026 revenue of $193.4 million, up 94% from about $99.7 million in Q1 2025, derived from the reported growth rate. Management forecast lower core gross margin in Q2 than Q1. The market data provider’s calendar, captured August 26, scheduled the next report for November 10, 2026; that was not an issuer filing, and the date could move. Compare the next reported margin with management’s Q2 direction.
• Cash conversion and deployment. Look for filed cash-flow statements, shipped systems, active capacity and customer sales. A deployment plan does not measure use.
• Price versus the listing. The DeadRisk market layer recorded a September 30, 2026, close of $177.65 per share, down 8.9% from the prior close and 3.6% over 30 days. It was 4.0% below the May IPO price and 42.9% below the May first-day close, derived. Those price gaps do not establish a change in demand or margins.

Cerebras Systems lives or dies by the same constraint as these names — small equal-weighted groups, one constraint each. Not investment products: see all categories.